RECRUITINGOBSERVATIONAL
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
About This Trial
A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.
Who May Be Eligible (Plain English)
Who May Qualify:
- Subjects born in Galicia from April 1st, 2023 and March 1st, 2026
Who Should NOT Join This Trial:
- No specific criteria has been reported
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Subjects born in Galicia from April 1st, 2023 and March 1st, 2026
Exclusion Criteria:
* No specific criteria has been reported
Treatments Being Tested
BIOLOGICAL
Nirsevimab
Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
Locations (1)
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain